


- Discovering and developing novel small molecule drugs, with an initial focus on underserved needs in **Myelodysplastic Syndromes (MDS)**
- Founded in 1998; Publicly traded (Nasdaq: ONTX) since 2013
- Phase 3 “INSPIRE” trial with IV rigosertib for Higher-Risk MDS patients after failure of front-line therapies is progressing after promising interim analysis, with over 75% enrollment. **Full enrollment projected in 2H2019.** Currently, there are no approved drugs for 2nd line patients with MDS.
- Protocol and special protocol assessment (SPA) for Phase 3 trial for oral rigosertib + azacitidine combination for front-line indications in MDS submitted to FDA in Dec-18, with ongoing protocol finalization based on FDA feedback.
- Rigosertib is patent-protected until **2037** and has **orphan designation for MDS.**
- Pipeline of targeted anti-cancer agents, including a CDK4/CDK6 + ARK5 inhibitor ON 123300

LEAD CANDIDATE RIGOSERTIB

INSPIRE randomized controlled pivotal trial with IV rigosertib for 360 patients, with 2:1 randomization, rigosertib treatment group vs. physician’s choice. Endpoint is overall survival, 288 events.

INSPIRE is based on learnings from prior trial of 299 patients:



The oral formulation of rigosertib in combination with Azacitidine, the current standard of care, has completed Phase 2 trials in front-line Higher-Risk MDS patients. A randomized trial in **first-line** Higher-Risk MDS patients is planned in which oral rigosertib + azacitidine will be compared to azacitidine + placebo.

Evaluable for response	29*
Overall response per IWG 2006	26 (90%)
CR+PR	10 (34%)
Complete remission (CR)	10 (34%)
Partial remission (PR)	0
Marrow CR + Hematologic Improvement	5 (17%)
Hematologic Improvement alone	3 (10%)
Marrow CR alone	8 (28%)
Stable disease	3 (10%)
Progression	0
Median duration of response (months)	12.2 (range, 0.1-24.2+)
Median duration of treatment (months)	7.8 (range, 0.7-25.1+)
Median time to initial/best response (cycles)	1/4

* Includes 2 patients treated with non-HMA, prior chemotherapy

Initial Focus on Rigosertib in MDS

Higher-Risk MDS:
Full enrollment expected
2H2019

**Lower-risk
MDS:**
Phase 2 trials

Additional indications
Rare diseases
(RASopathies) funded by

CDK targeted NCE

ONTX LICENSING OPPORTUNITIES

Patent-protected, differentiated small molecule compounds

Compound	Target	Stage	Next Step	Other Agents	Patents	Licensing Territories Available
<i>Clinical Stage</i>						
Rigosertib	<ul style="list-style-type: none"> RAS pathway MDS initial indication 	Phase 3	Top-line data in 2H2019	Only HMAs approved for MDS	Worldwide issued and pending to 2037	Europe, US, Canada, Middle East, Africa
<i>Advanced pre-IND stage</i>						
ON 123300	CDK4/6; ARK5	IND in 2Q2019	IND prep underway	Palbociclib	Issued US, EP	Ex-China rights

For further information please visit our website: www.onconova.com